Margetuximab
Margetuximab is a chimeric IgG monoclonal antibody against HER2 designed for the treatment of cancer.
This drug was created by Raven biotechnologies, which was later acquired by MacroGenics. It was engineered to increase affinity for CD16A polymorphisms and decrease affinity for FcγRIIB, an inhibitory receptor.
It binds to the same target as trastuzumab, on the HER2 receptor.
It is in phase 3 clinical trials for combination therapy in metastatic breast cancer in collaboration with Merck. Phase II trials are also in progress for gastric cancer and esophageal cancer.History
In June 2020, it received orphan drug designation from the U.S. Food and Drug Administration.
